RxDoctor Payments Data

John Norris, MD

Allergy & Immunology · Charlotte, NCNPI 1114952322

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $148,147 of the $198,252 with a category attached, or 74.7%. 43 manufacturers reported payments, led by GSK at 48.9% of the total. Reporting peaked in 2022 at $50,478 and has fallen 63.4% since, to $18,452 in 2025. Among allergy & immunology clinicians in NC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$198,252in general payments, 2019–2025

Across 1,334 payments — averaging $148.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$97K
  • Regeneron Healthcare Solutions, Inc.$39K
  • Bristol Myers Squibb$17K
  • AstraZeneca$17K
  • Sanofi$11K
  • Pfizer$2K
  • plus $15K from 37 others

What the payments were for

  • Consulting fees$18,2979%
  • Speaking & faculty fees$148,14775%
  • Travel & lodging$2,4091%
  • Food & beverage$29,27115%
  • Education$1280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$198,252 in reported general payments places this provider in the 90th percentile of 140 allergy & immunology providers in North Carolina.

See all allergy & immunology providers in North Carolina

Medicare billing

Part B allowed, 2024
$691,654
Medicare patients
624
Services billed
31,710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrladeyoBerotralstat Hydrochloride12$528,931
CuvitruImmun Glob G(Igg)/Gly/Iga Ov5047$378,055
HyqviaIgg/Hyaluronidase,recombinant39$288,291
TezspireTezepelumab-Ekko45$184,066
Trelegy ElliptaFluticasone/Umeclidin/Vilanter164$127,080
Dupixent PenDupilumab31$118,244
Aralast NpAlpha-1-Proteinase Inhibitor11$112,173
HizentraImmun Glob G(Igg)/Pro/Iga 0-5014$74,149
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5013$65,081
XolairOmalizumab11$55,684
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5018$51,770
Dupixent SyringeDupilumab13$50,622
Breztri AerosphereBudesonide/Glycopyr/Formoterol49$32,447
Breo ElliptaFluticasone/Vilanterol45$20,347
Epinephrine52$12,607

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Cuvitru, Hyqvia, Gammagard Liquid$1,836$731,42699 claims
Biocryst US Sales Co., LLCOrladeyo$679$528,93112 claims
AstraZenecaTezspire, Breztri Aerosphere, Symbicort$16,745$221,955110 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$96,866$151,258220 claims
CSL BehringHizentra, Privigen$925$125,91932 claims
Hikma Pharmaceuticals USAEpinephrine, Ryaltris$103$15,66863 claims
Optinose US, Inc.Xhance$1,233$9,78412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 140 allergy & immunology providers in North Carolina.

Other allergy & immunology in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →